Do Cardioselective β-Adrenoceptor Antagonists Reduce Mortality in Diabetic Patients with Congestive Heart Failure?

Abstract

These results extend prior observations that patients with diabetes and CHF may not accrue the same mortality benefit from CSB therapy as patients without diabetes, and warrant further prospective investigation.

Beta-blocker therapy and prognosis of heart failure patients with new-onset diabetes mellitus

“…Our results and effects size are in agreement with those of the previous retrospective subgroup analyses of clinical trials on patients with HFdEF and DM, and extend those observations to all the HF patients with DM, including women and men, as well as those with HFpEF and HFdEF. bB increase the risk of DM .…”

“…The influence of the treatment with beta‐blockers (bB) on the prognosis of heart failure (HF) patients with diabetes mellitus (DM) has not been established. Available data are retrospective subgroup analyses of the landmark clinical trials about the effects of cardio‐selective bB on the prognosis of patients with HF , and some observational studies . These studies included mostly hospitalised young males with HF and depressed ejection fraction (HFdEF) and low comorbidity .…”

“…Available data are retrospective subgroup analyses of the landmark clinical trials about the effects of cardio-selective bB on the prognosis of patients with HF (1-3), and some observational studies (4)(5)(6). These studies included mostly hospitalised young males with HF and depressed ejection fraction (HFdEF) and low comorbidity (1)(2)(3)(4)(5)(6). Therefore, more than one half of the HF population has not been studied (patients with HFpEF and women), and the patients included are not representative of the general HF population (elderly patients with comorbidity).…”

Acute heart failure in patients with diabetes mellitus: Clinical characteristics and predictors of in-hospital mortality

“…However, the length of hospital stay and rehospitalization rate was greater in this cohort. The increased mortality risk described in the studies mentioned above derived from monitoring of patients for a longer follow-up period [2,[10][11][36][37][38][39][40][41][42][43][44][45][46]. Finally, our observation regarding the detrimental effects of diabetes on in-hospital outcomes of AHF patients may be explained by other systemic conditions, such as renal dysfunction, anemia and obesity which are more frequent in this patient group, as well as by the higher frequency of ACS as a precipitating factor for AHF.…”

The role of glycemia in acute heart failure patients

“…However, in OPTIMIZE-HF registry no difference in hospital, 60-and 90-days mortality between these two groups of AHF patients can be demonstrated [16]. These differences between registries can be explained with more precise and intensive AHF treatment of diabetics in OPTIMIZE-HF, and with longer follow-up period in other registries [40][41][42][43][44][45][46][47][48][49][50][51][52][53][54][55][56][57][58]. In addition, in both registries, the length of hospitalization and rehospitalization rate was higher in diabetic group.…”